To assess if tumor bulk contributes to the immune landscape we observe in Figure 3, we repeated the tail vein experiment while controlling for tumor bulk by injecting four-times the number of control KPL cells relative to EphA2-overexpressing KPL cells. The gene discussed is EPHA2; the disease is neoplasm.